Intranasal Administration of
N-acetyl-L-cysteine
nanocarrier
neurodegeneration
nose-to-brain
spinal cord
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 Nov 2022
24 Nov 2022
Historique:
received:
04
10
2022
revised:
11
11
2022
accepted:
22
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Intranasal administration is a promising route for direct drug delivery to the brain; its combination with nanocarriers enhances delivery. We have previously shown that intranasal administration combined with PEG-PCL-Tat (a nanocarrier) efficiently delivers drugs to the brain and exhibits excellent therapeutic efficacy against brain diseases. We aimed to clarify whether intranasal administration combined with PEG-PCL-Tat represents a useful drug delivery system (DDS) for amyotrophic lateral sclerosis (ALS) pharmacotherapy. We used
Identifiants
pubmed: 36559085
pii: pharmaceutics14122590
doi: 10.3390/pharmaceutics14122590
pmc: PMC9785447
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP21J10187, JP20H04537, 22J23853, 22K19921
Références
J Control Release. 2013 Dec 28;172(3):782-94
pubmed: 24075927
Oxid Med Cell Longev. 2020 Jan 29;2020:1020673
pubmed: 32089764
Neurobiol Dis. 2003 Aug;13(3):213-21
pubmed: 12901835
Science. 1994 Jun 17;264(5166):1772-5
pubmed: 8209258
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):438-445
pubmed: 29221425
Acta Pharm Sin B. 2016 Jul;6(4):352-8
pubmed: 27471676
Mol Pharm. 2014 May 5;11(5):1471-8
pubmed: 24708261
J Biol Chem. 2003 Oct 24;278(43):42625-36
pubmed: 12882958
Cerebellum. 2007;6(4):308-14
pubmed: 17853088
Exp Neurol. 2013 Sep;247:447-455
pubmed: 23353638
J Control Release. 2018 Sep 28;286:467-484
pubmed: 30081144
J Neurosci Methods. 2018 Jun 1;303:30-40
pubmed: 29614295
Pharmaceutics. 2019 Sep 15;11(9):
pubmed: 31540164
J Control Release. 2021 Apr 10;332:493-501
pubmed: 33647429
J Control Release. 2018 Jan 28;270:89-100
pubmed: 29199063
Drug Deliv Transl Res. 2022 Apr;12(4):862-880
pubmed: 34731414
Mol Pharm. 2016 Mar 7;13(3):1004-11
pubmed: 26795701
Neuroreport. 2000 Aug 3;11(11):2491-3
pubmed: 10943709
Bioorg Med Chem. 2018 Jun 1;26(10):2888-2905
pubmed: 29170026
Pharmaceuticals (Basel). 2012 Oct 15;5(10):1092-102
pubmed: 24281259
Eur J Pharm Biopharm. 2020 Jul;152:85-94
pubmed: 32387702
J Control Release. 2022 Apr;344:225-234
pubmed: 35296406
J Vis Exp. 2018 Nov 14;(141):
pubmed: 30507914
NeuroRx. 2005 Jan;2(1):3-14
pubmed: 15717053
Nat Neurosci. 2002 Jun;5(6):514-6
pubmed: 11992114
Pharmaceutics. 2019 Nov 12;11(11):
pubmed: 31726721
Sci Rep. 2019 Feb 22;9(1):2621
pubmed: 30796294
Nature. 2016 Nov 10;539(7628):197-206
pubmed: 27830784
Front Cell Neurosci. 2017 Mar 21;11:80
pubmed: 28377696
Life Sci. 2018 Feb 15;195:44-52
pubmed: 29277310
Int J Pharm. 2010 Aug 30;396(1-2):229-38
pubmed: 20600726
Sci Rep. 2017 Oct 10;7(1):12924
pubmed: 29018285
Biomaterials. 2013 Dec;34(36):9220-6
pubmed: 23992922
Chem Pharm Bull (Tokyo). 2020;68(7):567-582
pubmed: 32611994
Ann Neurol. 1998 Aug;44(2):293
pubmed: 9708560
Neurobiol Dis. 2005 Apr;18(3):509-22
pubmed: 15755678
Exp Neurol. 2008 Oct;213(2):448-55
pubmed: 18718468
Toxicology. 2007 Jan 5;229(1-2):33-41
pubmed: 17097207
J Control Release. 2018 Jul 10;281:139-177
pubmed: 29772289
Mol Pharm. 2018 Mar 5;15(3):1105-1111
pubmed: 29338251
Pharmaceutics. 2018 Mar 15;10(1):
pubmed: 29543755
J Cereb Blood Flow Metab. 2015 Mar;35(3):371-81
pubmed: 25492117
Carcinogenesis. 1995 Sep;16(9):2099-106
pubmed: 7554060
Biochim Biophys Acta. 2013 Aug;1830(8):4117-29
pubmed: 23618697